KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Supernus Pharmaceuticals (SUPN) Receivables - Net (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Receivables - Net for 15 consecutive years, with $187.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 32.18% to $187.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $187.8 million, a 32.18% increase, with the full-year FY2025 number at $187.8 million, up 32.18% from a year prior.
  • Receivables - Net was $187.8 million for Q4 2025 at Supernus Pharmaceuticals, up from $171.3 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $187.8 million in Q4 2025 to a low of $127.1 million in Q1 2021.
  • A 5-year average of $149.0 million and a median of $145.3 million in 2022 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: decreased 13.61% in 2023, then surged 32.18% in 2025.
  • Supernus Pharmaceuticals' Receivables - Net stood at $148.9 million in 2021, then increased by 11.12% to $165.5 million in 2022, then decreased by 12.9% to $144.2 million in 2023, then decreased by 1.44% to $142.1 million in 2024, then surged by 32.18% to $187.8 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Receivables - Net are $187.8 million (Q4 2025), $171.3 million (Q3 2025), and $140.8 million (Q2 2025).